Suzanne Staples
Durban, ZN, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Routine immunization uptake and timeliness in young children exposed to multidrug-resistant tuberculosis: A secondary analysis of the Tuberculosis Child Multidrug-Resistant Preventive Therapy multi-site randomised controlled trial.
Journal: BMC global and public health
Published: August 07, 2025
Factors Predictive of Early Discontinuation of Preventive Treatment in Children With Household Exposure to Multidrug-resistant Tuberculosis.
Journal: Open forum infectious diseases
Published: June 22, 2025
Risk of Tuberculosis Infection in Young Children Exposed to Multidrug-resistant Tuberculosis in the TB-CHAMP Multi-site Randomized Controlled Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 21, 2025
Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis.
Journal: The New England journal of medicine
Published: December 18, 2024
Children's preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations.
Journal: IJTLD open
Published: October 29, 2024
Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment.
Journal: IJTLD open
Published: October 24, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: December 18, 2023
Patients' priorities around drug-resistant tuberculosis treatment: A multi-national qualitative study from Mongolia, South Africa and Georgia.
Journal: Global public health
Published: July 11, 2023
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.
Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: March 25, 2021
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Journal: The Lancet. Respiratory medicine
Published: December 11, 2018
Last Updated: 09/26/2026